Paradis Valérie, Bièche Ivan, Dargère Delphine, Laurendeau Ingrid, Laurent Christophe, Bioulac Sage Paulette, Degott Claude, Belghiti Jacques, Vidaud Michel, Bedossa Pierre
Centre National de la Recherche Scientifique FRE 2443, Faculté de Pharmacie, Paris V., France.
Am J Pathol. 2003 Aug;163(2):733-41. doi: 10.1016/S0002-9440(10)63700-5.
The aim of this study was to develop and validate a molecular index for the diagnosis of hepatocellular carcinoma (HCC) based on genes whose specificity and level of expression are the most discriminating for the diagnosis of HCC. The level of expression of 219 genes was assessed with a real-time reverse transcription-polymerase chain reaction approach in a training set of samples including normal livers (15), cirrhosis (12), and HCC (16). The most informative genes were selected for the molecular index. This index was prospectively validated in a new set of 40 samples (testing set) and in a set of 45 cirrhotic macronodules. 44 out of the 219 genes were differentially expressed in HCC. 13 out of these 44 genes were finally selected for the molecular index according to their diagnostic performance and after exclusion of most redundant genes. Using this index, 42 out of 43 samples of the training set and 39 out of the 40 samples of the testing set were correctly ranked as HCC or not HCC (normal liver or cirrhosis). The index also enabled correct ranking of 44 out of 45 cirrhotic macronodules into 2 groups: benign (including macroregenerative and dysplastic macronodules) and malignant macronodules. This molecular diagnostic index is an efficient tool both for identification of overt HCC as well as minute lesions (cirrhotic macronodules). It might be useful to correctly diagnose borderline lesion or small well-differentiated hepatocellular carcinomas whose diagnosis is often difficult on a histopathological basis.
本研究的目的是基于特异性和表达水平对肝细胞癌(HCC)诊断最具鉴别力的基因,开发并验证一种用于HCC诊断的分子指标。采用实时逆转录 - 聚合酶链反应方法,在包括正常肝脏(15例)、肝硬化(12例)和HCC(16例)的训练样本集中评估了219个基因的表达水平。为分子指标选择了最具信息量的基因。该指标在一组新的40个样本(测试集)和一组45个肝硬化大结节中进行了前瞻性验证。219个基因中有44个在HCC中差异表达。根据其诊断性能并排除大多数冗余基因后,最终从这44个基因中选择了13个用于分子指标。使用该指标,训练集的43个样本中有42个、测试集的40个样本中有39个被正确分类为HCC或非HCC(正常肝脏或肝硬化)。该指标还能将45个肝硬化大结节中的44个正确分为两组:良性(包括大再生性和发育异常性大结节)和恶性大结节。这种分子诊断指标是识别显性HCC以及微小病变(肝硬化大结节)的有效工具。对于正确诊断临界病变或组织病理学诊断往往困难的小的高分化肝细胞癌可能有用。